Skip to main content
Log in

The economic burden of Hepatitis B in Germany

  • Published:
European Journal of Epidemiology Aims and scope Submit manuscript

Abstract

Despite the widespread distribution of Hepatitis B virus (HBV) infection and the ongoing controversy about HBV immunization, surprisingly few published studies examined in detail the economic impact of HBV infection in Europe. Therefore, we investigated a cohort of 180 patients throughout Germany to evaluate the economic burden of HBV-associated disease. In 58 patients with acute and 122 patients with chronic HBV infection, cost-consuming events including direct medical costs and work-loss costs were documented. The direct costs were DM 7702 (95% confidence interval (CI): 5473–9931) for each acute HBV infection and DM 4247 (CI: 1601–6893) per patient-year of chronic HBV infection, with marked differences between different stages of HBV disease. The derived overall costs (1997 price levels) per year were DM 10,018 (CI: 7613–12,421) and DM 4860 (CI: 2185–7536), respectively. Based on crude population-based estimates (30,000 acute and 420,000 chronic HBV cases), we calculated the total HBV-related costs in Germany to exceed DM 1200 millions in 1997 (CI: 924.2–1536.7), with the treatment of patients with chronic active HBV disease as the major cost determinant. Previously published data from Germany probably overestimated the financial impact of acute HBV infection. In summary, our results illustrate the ongoing economic importance of this potentially life-threatening, but preventable disease and support the call for more accurate HBV surveillance and control in Germany.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Arnot R. The evolving efforts to control hepatitis B virus. Pediatr Infect Dis J 1998; 17 (7 Suppl): S26-S29.

    Google Scholar 

  2. Brechot C, Jaffredo F, Lagorce D, et al. Impact of HBV, HCV and GBV-C/HGV on hepatocellular car-cinomas in Europe. J Hepatol 1998; 29(2): 173–183.

    Google Scholar 

  3. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337(24): 1733–1745.

    Google Scholar 

  4. Goudeau A. Epidemiology and eradication strategy for hepatitis B in Europe. European Regional Study Group. Vaccine 1990; 8 (Suppl): S113-S116.

    Google Scholar 

  5. Iwarson S, Jilg W, Stroffolini T. Substantial decline of notified hepatitis B in major parts of Europe after 1985. Scand J Infect Dis 1994; 26(1): 19–22.

    Google Scholar 

  6. Van Damme P, Vellinga A. Epidemiology of hepatitis B and C in Europe. Acta Gastroenterol Belg 1998; 61(2): 175–182.

    Google Scholar 

  7. Robert-Koch-Institut. Zur Situation bei ausgewählten meldepflichtigen Infektionserkrankungen im Jahr 1997. Teil 3: Virushepatitiden. Epidemiologisches Bulletin 1998; 13: 85–89.

    Google Scholar 

  8. Jefferson T, Demicheli V. Is vaccination against hepatitis B efficient? A review of world literature. Health Econ 1994; 3(1): 25–37.

    Google Scholar 

  9. Mortimer PP, Miller E. Commentary: Antenatal screening and targeting should be sufficient in some countries. Br Med J 1997; 314(7086): 1036–1037.

    Google Scholar 

  10. Goldberg D, McMenamin J. The United Kingdom's hepatitis B immunisation strategy-Where now? Commun Dis Public Health 1998; 1(2): 79–83.

    Google Scholar 

  11. Struve J, Giesecke J. Cost of acute hepatitis B infection in Swedish adults. Scand J Infect Dis 1993; 25(6): 693–697.

    Google Scholar 

  12. Van Damme P, Tormans G, Beutels P, van Doorslaer E. Hepatitis B prevention in Europe: A preliminary economic evaluation. Vaccine 1995; 13(Suppl 1): S54-S57.

    Google Scholar 

  13. Szucs TD, Schramm W. Economic evaluation of medical therapy-Methodological principles. Zentralbl Chir 1995; 120(8): 577–583.

    Google Scholar 

  14. Fleiss JL. An introduction to applied probability. In: Fleiss JL (ed.), Statistical methods for rates and proportions. 2 ed. vol. 1. New York, Chichester, Brisbane, Toronto: John Wiley & Sons, 1981: 1–19.

    Google Scholar 

  15. Lahaye D, Strauss P, Baleux C, van Ganse W. Cost-benefit analysis of hepatitis-B vaccination. Lancet 1987; 2(8556): 441–443.

    Google Scholar 

  16. Williams JR, Nokes DJ, Medley GF, Anderson RM. The transmission dynamics of hepatitis B in the UK: A mathematical model for evaluating costs and effectiveness of immunization programmes. Epidemiol Infect 1996; 116(1): 71–89.

    Google Scholar 

  17. Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. Br Med J 1997; 314(7086): 1033–1036.

    Google Scholar 

  18. Szucs TD, Smala A, Berger K, Windorfer A. Economic evaluation of various hepatitis B immunisation strate-gies in children and adolescents. Med Klin 1998; 93(8): 468–477.

    Google Scholar 

  19. Adler MW, Belsey EM, McCutchan JA, Mindel A. Should homosexuals be vaccinated against hepatitis B virus? Cost and benefit assessment. Br Med J (Clin Res Ed) 1983; 286(6378): 1621–1624.

    Google Scholar 

  20. Rivera F, Lissen E, Vazquez R, et al. Cost-benefit analysis of a program for vaccination against hepatitis B in health personnel of a hospital. Med Clin (Barc) 1984; 83(15): 611–614.

    Google Scholar 

  21. Lange W, Masihi KN. Epidemiology and economic importance of hepatitis B in the Federal Republic of Germany. Postgrad Med J 1987; 63 (Suppl 2): 21–26.

    Google Scholar 

  22. Szucs TD, Muller EI, Berger K. Cost structure of hepatitis B infection. Fortschr Med 1997; 115(4): 47–48.

    Google Scholar 

  23. Hoffmann V, Richter GM, Funk H, Otto G, Kauffmann GW. Liver transplantation and diagnostic radiology: socioeconomic aspects. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996; 165(2): 113–117.

    Google Scholar 

  24. Deutsches Kuratorium für Organspende, Jahresbericht 1998. Bad Honnef, Germany.

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harbarth, S., Szucs, T., Berger, K. et al. The economic burden of Hepatitis B in Germany. Eur J Epidemiol 16, 173–177 (2000). https://doi.org/10.1023/A:1007624415699

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007624415699

Navigation